Pharma

  • CVS
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    CVS to pay $315M to settle opioid prescribing allegations

    Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.

    By Sydney Halleman • Oct. 14, 2026
  • A 3D illustration of a pair of lungs inside the rib cage.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers dips on ‘confounding’ lung drug results

    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

    By • Oct. 12, 2026
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • Illustration of a large blue ocean wave cresting against a pale blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma’s $500B patent problem will come in waves — not as a cliff

    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

    By Sy Mukherjee • Oct. 12, 2026
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

    By • Oct. 8, 2026
  • Photomicrograph of a diffuse large B-cell lymphoma (DLBCL) a type of non-Hodgkin lymphoma.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

    The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

    By • Oct. 6, 2026
  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    The top biopharma conferences in 2027

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

    By • Oct. 6, 2026
  • Promotional graphic for Season 2 of The Progress Profile: Alzheimer’s Research in Focus, featuring the Pearson and BioPharma Dive logos on a dark blue background with abstract glowing blue wave patterns on the right.
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

    This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

    By BioPharma Dive's studioID • Oct. 6, 2026
  • Black and white picture of a couple
    Image attribution tooltip

    Created with the assistance of Midjourney in the UK

    Image attribution tooltip
    Sponsored by Diaceutics

    Precision for All: Closing the gap between innovation and impact

    Why diagnostic-driven therapies need a new commercialization model to reach more eligible patients.

    By Sarah Heming, interim VP of Strategic Marketing, Diaceutics • Oct. 5, 2026
  • A sign spelling Novartis hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

    In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.

    By • Oct. 2, 2026
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    3 takeaways from a European obesity scientific meeting

    Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

    By • Oct. 1, 2026
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi, Regeneron broaden alliance to find their next Dupixent

    The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.

    By • Oct. 1, 2026
  • A close-up of a child's hands with red, irritated skin on the wrist.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer’s eczema drug clears skin in mid-stage trial

    Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.

    By • Oct. 1, 2026
  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

    A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. 

    By • Sept. 30, 2026
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA starts review of Roche’s multiple sclerosis pill

    The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

    By • Sept. 30, 2026
  • Digital tablet displaying “AI AGENTS” with connected icons representing data, cloud computing and automated tools.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    An AI agent made a tiny drug R&D mistake. Then it kept going.

    The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

    By Sy Mukherjee • Sept. 30, 2026
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

    The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

    By • Sept. 29, 2026
  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

    The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

    By • Sept. 28, 2026
  • Two woman taking a selfie outside
    Image attribution tooltip

    AdobeStock

    Image attribution tooltip
    Sponsored by Azurity Pharmaceuticals

    Kids shouldn’t have to organize childhood around medicine

    Fewer shots, no hour-long pharmacy runs: two families show what medicine built for real life means.

    By Ron Scarboro, CEO, Azurity Pharmaceuticals • Sept. 28, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Novo’s rise and fall and AI biotechs’ big haul

    The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.

    By • Sept. 25, 2026
  • EU Visa Mastercard card networks Europe
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe

    Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”

    By Kristin Jensen • Sept. 23, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

    By • Sept. 22, 2026
  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo talks up drug launches in effort to win back investors

    At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

    By • Sept. 21, 2026
  • Female doctor talking with a diverse team of medical professionals during a meeting around a conference table in a hospital
    Image attribution tooltip
    Goodboy Picture Company via Getty Images
    Image attribution tooltip
    Sponsored by Lucid Group

    Are healthcare systems really ready for GLP-1s?

    New GLP-1 therapy indications mean new challenges for pharma companies, from care to consumer trust.

    Sept. 21, 2026
  • DR. meeting with client
    Image attribution tooltip
    Permission granted by Walgreens
    Image attribution tooltip
    Sponsored by Walgreens Specialty Pharmacy

    Behind the outcomes: How whole-patient support is reshaping oncology care

    As oncology care grows personalized and home-based, support around treatment becomes as vital as treatment.

    Sept. 21, 2026
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo partners with Orbis, deepening investment in oral peptide drugs

    The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

    By • Sept. 17, 2026